Chelsea Therapeutics confirms FDA approval of Northera, halt lifted at 5:25


The FDA confirms it approved Chelsea Therapeutics' (CHTP) Northera capsules for the treatment of neurogenic orthostatic hypotension.

Northera will contain a boxed warning to alert doctors and patients about applicable risks, and the package insert indicates that effectiveness beyond two weeks of treatment has not yet been demonstrated, but there's no restriction on prescription use.

CHTP calls the approval "an extraordinary achievement."

Shares to resume trading at 5:25.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs